drugset
drugset / Trial / NCT02472236

Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects

NCT02472236 ↗

Phase 1 Completed 16 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

To assess the effect of PEX168 doses on the pharmacokinetics of digoxin in healthy subjects.To provide a scientific basis for clinical drug combination of PEX168. To assess the safety of single doses of digoxin administered with and without PEX168

Timeline

Start
2015-06-08
Primary completion
2015-09-24
Completion
2016-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.5 mg Oral
Subject PEGLOXENATIDE Peptide 200 ug Subcutaneous

Indications

No indication recorded.